---
document_datetime: 2025-06-30 09:59:25
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/emtricitabine-tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: emtricitabine-tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.5846765
conversion_datetime: 2025-12-19 04:36:44.826986
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Emtricitabine/Tenofovir disoproxil Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | This was an application for a group of | 27/06/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000279174   | variations. A. ADMINISTRATIVE CHANGES - A.4 Change in thename and/or addressof:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof theactive substance (where specified in the technical   | PL   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

<div style=\"page-break-after: always\"></div>

| A.5Changeinthename and/oraddress of a manufacturer/importerofthefinished product (including batch release or quality control testing sites)-A.5.bThe activities for which the manufacturer/importer is responsibledonotincludebatchrelease- Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of:a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance(where specified in the technical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or amanufacturerofanovelexcipient(where specified in the technical dossier)- Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |             |                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-------------------|
| Variation type II /                   | B.IACTIVESUBSTANCE-B.I.zSubstantial updates to Mod.3.2.S or the ASMF - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27/03/2025 | N/A |             | EMA/VR/0000177324 |
| Variation type II / EMA/VR/0000223057 | B.IACTIVESUBSTANCE-B.I.zSubstantial updates to Mod.3.2.S or the ASMF- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/02/2025 | N/A |             |                   |
| Variation type IB / EMA/VR/0000175866 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal productsfollowingassessmentofthesame change for the reference product-C.1.2.a Implementation of change(s) for which no new additional datais required to be submitted by theMAH-Accepted Toupdatesection4.4of theSmPCtoamend awarning/precautionregardingboneeffects. Updateofsection4.8oftheSmPCtoadd the adverse reaction bone mineral density decreased with a frequency common. The packageleaflet hasbeen updated accordingly.In addition,theMAH has updated the list of local representatives for ES,PL, CY,AT,IE and IT and minor correctionhavebeenmadetothe | 11/06/2024 |     | SmPC and PL |                   |

<div style=\"page-break-after: always\"></div>

| translations for consistency.   |
|---------------------------------|